Novartis Aktie
91,74
EUR
+0,86
EUR
+0,95
%
86,14
CHF
+0,76
CHF
+0,89
%
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Deutsche Bank AG | 110,00 CHF | - | 30.11.2023 | |
| Barclays Capital | 85,00 CHF | - | 29.11.2023 | |
| UBS AG | 90,00 CHF | - | 28.11.2023 | |
| Jefferies & Company Inc. | 100,00 CHF | - | 28.11.2023 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 74,00 CHF | - | 19.10.2023 | |
| JP Morgan Chase & Co. | 90,00 CHF | - | 05.10.2023 | |
| Morgan Stanley | 98,00 CHF | - | 25.09.2023 | |
| Credit Suisse Group | 90,00 CHF | - | 26.04.2023 | |
| Goldman Sachs Group Inc. | 106,00 CHF | - | 13.02.2023 | |
| Bernstein Research | 90,00 CHF | - | 08.12.2022 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 5 | 2 | 1 | 119,06 GBP | - |
| Bayer | 4 | 7 | 0 | 55,10 EUR | +77,86% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 2 | 0 | 25,40 EUR | +39,71% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 3 | 3 | 2 | 15,87 GBP | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 1 | 197,50 EUR | +22,29% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 2 | 93,30 CHF | - |
| Pfizer Inc. | 3 | 4 | 0 | 41,14 USD | +39,93% |
| Roche AG (Genussschein) | 3 | 5 | 2 | 291,78 CHF | - |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 7 | 2 | 1 | 105,10 EUR | +21,70% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |